Filtyp
Are you enrolled in the Biomedicine Master Programme at Lund University? The course in metabolic diseases is part of the programme and is taught by staff at LUDC. The course provides students with specialisation in cell biology and human physiology. The course focuses on (some of the) endocrine and metabolic diseases that are included in the strong research areas at Lund University.The course star
https://www.ludc.lu.se/course-metabolic-diseases - 2026-08-29
Below you will find dissertations of relevance to the strategic research area EXODIAB (Excellence of Diabetes Research in Sweden). 2026Environmentally sustainable diets and human health - Nutritional adequacy, disease risk, and mortalityAnna StubbendorffMAFB in Pancreatic β-Cell Biology: From Developmental Regulation to Diabetes RiskSara BsharatNew Insights into Cardiopulmonary Comorbidity: Clinic
https://www.ludc.lu.se/ludc-ecn/doctoral-theses-phd-students - 2026-08-29
SRA Workshop series I would like to register for the workshop on Multidisciplinary impact pathways - Defining project outcomes, outputs and impact. Date: Tuesday November 22nd Time: 8.30-12.00 Location: LU Clinical Research Centre (Dept of Clinical Sciences Malmö) Malmö. Please register latest by November 15th. Surname (required) Family name (required) LU email address (required) I have t
https://www.ludc.lu.se/form/multidisciplinare-impact-pathways-defining-project-outcomes-outputs-and-impact - 2026-08-29
Emily Sonestedt’s group Our researchNutritional epidemiology uses epidemiological methods to examine the association between diet and disease. In our research group, we investigate whether food habits influence the risk of developing various diseases, including cardiovascular disease, type 2 diabetes, and cancer. We use large population studies, mainly the Malmö Diet and Cancer cohort, which was e
https://www.ludc.lu.se/research/nutritional-epidemiology - 2026-08-29
Peter Spégel’s group Our researchOur research aims to understand metabolism and how it is altered in diabetes and obesity. Our hope is that knowledge on metabolic dysregulation in obesity-associated diseases and changes in metabolism associated with life-style interventions can aid us in designing sustainable life-style recommendations. The overall purpose is to enhance our understanding of metabo
https://www.ludc.lu.se/research/diabetes-obesity-and-metabolism - 2026-08-29
Karin Stenkula’s group Our researchOur research is focused on exploring the molecular mechanisms regulating adipocyte function, both normal and in the insulin-resistant state, using experimental cell biology methods and sophisticated microscopy techniques at a single cell level. AimsOur overall aim is to identify the mechanisms that cause adipocyte dysfunction. Specifically, we want to understand
https://www.ludc.lu.se/research/glucose-transport-and-protein-trafficking - 2026-08-29
Nils Wierup’s group Our researchThe purpose of our research is to understand how each islet cell type and each enteroendocrine cell type in the gut is affected in type 2 diabetes. Impaired islet function is necessary for type 2 diabetes to develop. Less is known on the role of gut hormones in type 2 diabetes pathophysiology. By identifying type 2 diabetes-induced alterations we foresee that we wi
https://www.ludc.lu.se/research/neuroendocrine-cell-biology - 2026-08-29
Enming Zhang’s group Our researchThe deterioration of pancreatic islet cell functions is a prominent feature of diabetes. Islet cells express various cellular molecular sensors, for example ion channels. These respond to a variety of stimuli, such as voltage, chemical ligands, and mechanical/osmotic stimuli. The stimulus-sensor interactions typically regulate cellular functions to adapt to an abno
https://www.ludc.lu.se/research/diabetes-islet-pathophysiology - 2026-08-29
Harry Björkbacka’s group Our researchCardiovascular disease is the number one cause of death in people living with diabetes, and people with diabetes are twice as likely to have heart disease or suffer a stroke than people without diabetes. Cardiovascular disease is mainly caused by atherosclerosis, which is characterized by lipid deposition, chronic inflammation, immune cell accumulation, and fib
https://www.ludc.lu.se/research/experimental-cardiovascular-research - 2026-08-29
Lund University Diabetes Centre is home to about 30 research groups. Our scientists look for new treatments and drugs to prevent, delay, or cure diabetes. The research teams also work towards developing personalised care and treatment for patients with diabetes. Daniel Agardh's group Anna Blom's group João Duarte’s group Isabel Goncalves' group Philipp Kaldis’ group Marju Orho-Melander’s group Pe
https://www.ludc.lu.se/research - 2026-08-29
Leaders for work package 2: Charlotte Ling and Hindrik Mulder This work package (WP2) will take advantage of the large observational cohorts with corresponding samples and will use cutting edge technology for the discovery and validation of new genetic and non-genetic biomarkers. WP2 will also use established tools for the validation of biomarker candidates recently identified by LUDC investigator
https://www.ludc.lu.se/ludc-irc/biomarker-discovery-observational-prospective-studies - 2026-08-29
Lund University Diabetes Centre (LUDC) is a research centre dedicated to unravelling the mechanisms behind diabetes and its complications. Our vision at LUDC is to improve patient stratification and to undertake innovative translational studies that lead to better prevention and management of diabetes and its complications through precision diabetes medicine.At LUDC, more than 300 people work in a
https://www.ludc.lu.se/about-ludc - 2026-08-29
Researchers at LUDC are part of EXODIAB (Excellence of Diabetes Research in Sweden), a strategic research area at Lund University. The aim of EXODIAB is to develop new treatments and drugs to prevent or cure diabetes. The primary aim of EXODIAB is to develop new treatments and drugs that can prevent, delay, or cure diabetes and its complications. A second objective is to create improved conditions
https://www.ludc.lu.se/ludc/exodiab-strategic-research - 2026-08-29
Lund University Diabetes Centre (LUDC) is one of the largest diabetes research centres in the world with more than 300 members of staff. LUDC is working towards improved diagnosis, prevention, and treatment of diabetes and combines expertise in several fields to achieve this goal.The research centre gathers expertise in genetics, epidemiology, statistics, bioinformatics, molecular and cellular bio
https://www.ludc.lu.se/ludc/work-ludc - 2026-08-29
Lund University Diabetes Centre (LUDC) is a world-leading research centre in the field of diabetes research. Any gift from you, regardless of amount, is a powerful endorsement of our research. Diabetes research at LUDC spans a wide area. Scientists at LUDC study everything from genetic factors and how they interact with the environment to disease mechanisms in the insulin-producing cells and surro
https://www.ludc.lu.se/ludc/support-us - 2026-08-29
Lund University Diabetes Centre (LUDC) is led by a governing board. The governing board includes all the principal investigators at LUDC. Allan Vaag, Coordinator of LUDC and EXODIAB, and Lena Eliasson, Vice Coordinator of LUDC and EXODIAB, handle the daily operations at LUDC. The centre is led by a governing board that includes all the principal investigators at LUDC.The strategic research area EX
https://www.ludc.lu.se/ludc/organisation - 2026-08-29
Department of Clinical Sciences Malmö Head: Martin Ridderstråle The prevalence of obesity and type 2 diabetes (T2DM) is increasing worldwide. Although our therapeutic arsenal to beget these conditions and their consequences in the form of cardiovascular morbidity and mortality is increasing a lot still needs to be learned about the underlying mechanisms. This project deals with clinical care and t
https://www.ludc.lu.se/research-0/clinical-obesity - 2026-08-29
Leaders of work package 7: Jan Nilsson and Olle Melander This work package focuses on diabetes-driven cardiovascular disease (CVD). The mild age-related diabetes (MARD) cluster, together with the mild obesity-related diabetes (MOD) and the severe insulin-resistant diabetes (SIRD) has the highest risk of developing CVD.Central to the studies in this work package are a number of well-characterised c
https://www.ludc.lu.se/ludc-irc/mild-age-related-diabetes-mard-mechanisms-and-pathways - 2026-08-29
News from the Innovation Office.
https://www.ludc.lu.se/newsletters - 2026-08-29
Leaders of work package 5: Ola Hansson and Eva Degerman SIRD is a novel form of diabetes representing the most insulin resistant (both hepatic and peripheral) form, with most features of the metabolic syndrome but also hepatic steatosis. In this work-package we explore mechanisms and pathways relevant to insulin resistance in various organs and tissues, such as liver, adipose tissue, kidney, skele
https://www.ludc.lu.se/ludc-irc/severe-insulin-resistant-diabetes-sird-mechanisms-and-pathways - 2026-08-29
